2024 Q3 Form 10-Q Financial Statement
#000129397124000040 Filed on September 13, 2024
Income Statement
| Concept | 2024 Q3 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|
| Revenue | $10.61M | $18.57M | $7.834M |
| YoY Change | -14.36% | 680.05% | 12334.92% |
| Cost Of Revenue | $11.78M | $25.86M | $9.632M |
| YoY Change | 7.54% | 666.11% | 45766.67% |
| Gross Profit | -$1.169M | -$7.291M | -$1.798M |
| YoY Change | -181.35% | 632.76% | -4380.95% |
| Gross Profit Margin | -11.02% | -39.26% | -22.95% |
| Selling, General & Admin | $39.77M | $46.33M | $47.10M |
| YoY Change | -2.3% | 24.03% | 53.4% |
| % of Gross Profit | |||
| Research & Development | $23.17M | $25.07M | $33.77M |
| YoY Change | -49.03% | -45.67% | -26.42% |
| % of Gross Profit | |||
| Depreciation & Amortization | $15.34M | $15.47M | $25.40M |
| YoY Change | 1334.02% | 1329.67% | 1922.69% |
| % of Gross Profit | |||
| Operating Expenses | $62.94M | $71.40M | $80.88M |
| YoY Change | -26.96% | -14.49% | 5.57% |
| Operating Profit | -$66.92M | -$78.69M | -$82.67M |
| YoY Change | -21.02% | -1032.7% | 7.98% |
| Interest Expense | -$4.138M | $4.856M | -$14.44M |
| YoY Change | -268.62% | 71.89% | -4013.82% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $10.19M | $11.17M | $8.555M |
| YoY Change | -3.35% | 11.9% | 30.85% |
| Pretax Income | -$60.87M | -$69.80M | -$88.56M |
| YoY Change | -15.15% | -428.64% | -373.82% |
| Income Tax | -$100.0K | $0.00 | -$46.00K |
| % Of Pretax Income | |||
| Net Earnings | -$60.81M | -$69.80M | -$88.51M |
| YoY Change | -15.23% | -428.63% | -374.62% |
| Net Earnings / Revenue | -573.01% | -375.81% | -1129.87% |
| Basic Earnings Per Share | -$0.31 | -$0.36 | |
| Diluted Earnings Per Share | -$0.31 | -$0.36 | -$0.75 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 193.9M shares | 193.2M shares | 109.3M shares |
| Diluted Shares Outstanding | 193.9M shares | 193.2M shares |
Balance Sheet
| Concept | 2024 Q3 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $70.65M | $212.0M | $221.8M |
| YoY Change | -59.46% | -33.37% | 22.02% |
| Cash & Equivalents | $70.65M | $212.0M | $221.8M |
| Short-Term Investments | $0.00 | ||
| Other Short-Term Assets | $25.15M | $28.28M | $37.01M |
| YoY Change | 44.7% | -2.5% | 93.16% |
| Inventory | $53.94M | $30.31M | $22.92M |
| Prepaid Expenses | $7.553M | $11.51M | $14.80M |
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $150.8M | $271.6M | $281.7M |
| YoY Change | -38.96% | -22.64% | 41.2% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $62.59M | $90.37M | $65.94M |
| YoY Change | 527.69% | 936.55% | 604.29% |
| Goodwill | $5.646M | $5.646M | $5.646M |
| YoY Change | 0.0% | 0.0% | 0.0% |
| Intangibles | $9.780M | $10.24M | $10.44M |
| YoY Change | 82.19% | 82.5% | 114.42% |
| Long-Term Investments | $0.00 | ||
| YoY Change | -100.0% | ||
| Other Assets | $53.13M | $58.42M | $54.34M |
| YoY Change | 4.52% | 13.35% | 4.25% |
| Total Long-Term Assets | $314.2M | $359.9M | $337.5M |
| YoY Change | -14.27% | 5.33% | -5.05% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $150.8M | $271.6M | $281.7M |
| Total Long-Term Assets | $314.2M | $359.9M | $337.5M |
| Total Assets | $465.1M | $631.5M | $619.2M |
| YoY Change | -24.21% | -8.84% | 11.58% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $24.48M | $19.39M | $18.50M |
| YoY Change | 23.32% | 0.79% | -26.28% |
| Accrued Expenses | $87.50M | $88.46M | $88.79M |
| YoY Change | -27.98% | -3.37% | -12.0% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $70.60M | $69.00M | $0.00 |
| YoY Change | |||
| Total Short-Term Liabilities | $296.0M | $293.6M | $200.1M |
| YoY Change | 86.23% | 153.23% | 56.05% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $5.675M | $26.09M | $37.73M |
| YoY Change | |||
| Other Long-Term Liabilities | $1.079M | $92.00K | $92.00K |
| YoY Change | 1072.83% | 0.0% | 0.0% |
| Total Long-Term Liabilities | $1.079M | $92.00K | $92.00K |
| YoY Change | 1072.83% | 0.0% | 0.0% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $296.0M | $293.6M | $200.1M |
| Total Long-Term Liabilities | $1.079M | $92.00K | $92.00K |
| Total Liabilities | $470.8M | $500.4M | $424.6M |
| YoY Change | 20.4% | 48.06% | 18.43% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$4.500B | -$4.300B | -$4.260B |
| YoY Change | 9.49% | 8.31% | 6.78% |
| Common Stock | $1.917M | $1.913M | $1.905M |
| YoY Change | 78.99% | 79.79% | 129.52% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$5.786M | $131.0M | $194.5M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $465.1M | $631.5M | $619.2M |
| YoY Change | -24.21% | -8.84% | 11.58% |
Cashflow Statement
| Concept | 2024 Q3 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$60.81M | -$69.80M | -$88.51M |
| YoY Change | -15.23% | -428.63% | -374.62% |
| Depreciation, Depletion And Amortization | $15.34M | $15.47M | $25.40M |
| YoY Change | 1334.02% | 1329.67% | 1922.69% |
| Cash From Operating Activities | -$68.93M | -$74.70M | -$13.84M |
| YoY Change | 11.44% | -13.74% | -75.41% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $280.0K | $1.775M | $5.217M |
| YoY Change | -86.21% | 665.09% | 2.13% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $746.0K | $1.120M | $8.997M |
| YoY Change | -98.84% | -98.65% | -91.7% |
| Cash From Investing Activities | $466.0K | -$655.0K | $3.790M |
| YoY Change | -99.25% | -100.8% | -96.33% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -6.105M | $64.65M | 66.28M |
| YoY Change | 15162.5% | -50.45% | -57733.04% |
| NET CHANGE | |||
| Cash From Operating Activities | -68.93M | -$74.70M | -13.84M |
| Cash From Investing Activities | 466.0K | -$655.0K | 3.790M |
| Cash From Financing Activities | -6.105M | $64.65M | 66.28M |
| Net Change In Cash | -74.57M | -$10.69M | 56.23M |
| YoY Change | -39345.79% | -108.48% | 20.02% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$68.93M | -$74.70M | -$13.84M |
| Capital Expenditures | $280.0K | $1.775M | $5.217M |
| Free Cash Flow | -$69.21M | -$76.48M | -$19.05M |
| YoY Change | 8.34% | -11.93% | -68.96% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
193583000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
193583000 | shares |
| CY2023Q1 | us-gaap |
Revenues
Revenues
|
2381000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
25864000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
5512000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
68995000 | usd |
| CY2023Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
0 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
24363000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
21202000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
114212000 | usd |
| CY2023Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
84705000 | usd |
| CY2024Q1 | us-gaap |
Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
|
12000 | usd |
| CY2023Q1 | us-gaap |
Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
|
85000 | usd |
| CY2024Q1 | us-gaap |
Revenues
Revenues
|
18573000 | usd |
| CY2024Q1 | us-gaap |
Gross Profit
GrossProfit
|
-7291000 | usd |
| CY2023Q1 | us-gaap |
Gross Profit
GrossProfit
|
-3131000 | usd |
| CY2024Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
46329000 | usd |
| CY2023Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
37467000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
25072000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
41587000 | usd |
| CY2024Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
71401000 | usd |
| CY2023Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
79054000 | usd |
| CY2024Q1 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
0 | usd |
| CY2023Q1 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
92930000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-78692000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
10745000 | usd |
| CY2024Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2579000 | usd |
| CY2023Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2828000 | usd |
| CY2024Q1 | us-gaap |
Interest Expense
InterestExpense
|
4856000 | usd |
| CY2023Q1 | us-gaap |
Interest Expense
InterestExpense
|
4270000 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
11165000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
9627000 | usd |
| CY2024Q1 | us-gaap |
Income Loss Attributable To Parent
IncomeLossAttributableToParent
|
-69804000 | usd |
| CY2023Q1 | us-gaap |
Income Loss Attributable To Parent
IncomeLossAttributableToParent
|
18930000 | usd |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-69804000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
18930000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.36 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.18 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.36 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.18 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
193151000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
102920000 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
193151000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
103303000 | shares |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
|
0.0 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
|
0.0 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-312000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
984000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-312000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
984000 | usd |
| CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-70116000 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
19914000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
194537000 | usd |
| CY2024Q1 | blue |
Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
|
0 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
2571000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4054000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-312000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
131046000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
134333000 | usd |
| CY2023Q1 | blue |
Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
|
-195000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
7000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
227000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
130291000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5843000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
984000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
18930000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
290420000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-69804000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
18930000 | usd |
| CY2024Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
15469000 | usd |
| CY2023Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
6172000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3761000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5391000 | usd |
| CY2024Q1 | blue |
Noncash Research And Development Expense Finance Lease
NoncashResearchAndDevelopmentExpenseFinanceLease
|
0 | usd |
| CY2023Q1 | blue |
Noncash Research And Development Expense Finance Lease
NoncashResearchAndDevelopmentExpenseFinanceLease
|
1441000 | usd |
| CY2024Q1 | blue |
Noncash Lease Expense
NoncashLeaseExpense
|
5904000 | usd |
| CY2023Q1 | blue |
Noncash Lease Expense
NoncashLeaseExpense
|
7423000 | usd |
| CY2024Q1 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
0 | usd |
| CY2023Q1 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
92930000 | usd |
| CY2024Q1 | blue |
Inventory Excess Valuation Reserves
InventoryExcessValuationReserves
|
91000 | usd |
| CY2023Q1 | blue |
Inventory Excess Valuation Reserves
InventoryExcessValuationReserves
|
2583000 | usd |
| CY2024Q1 | blue |
Noncash Interest Related To Debt
NoncashInterestRelatedToDebt
|
-156000 | usd |
| CY2023Q1 | blue |
Noncash Interest Related To Debt
NoncashInterestRelatedToDebt
|
0 | usd |
| CY2024Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
10000 | usd |
| CY2023Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-237000 | usd |
| CY2024Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
777000 | usd |
| CY2023Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
108000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
13528000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
3689000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
7185000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
5331000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1454000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1260000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-10299000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-7206000 | usd |
| CY2024Q1 | blue |
Increase Decrease Accrued Interest Payable Under Finance Lease
IncreaseDecreaseAccruedInterestPayableUnderFinanceLease
|
-2936000 | usd |
| CY2023Q1 | blue |
Increase Decrease Accrued Interest Payable Under Finance Lease
IncreaseDecreaseAccruedInterestPayableUnderFinanceLease
|
-915000 | usd |
| CY2024Q1 | blue |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-2844000 | usd |
| CY2023Q1 | blue |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-6361000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
0 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-85000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-74676000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-71358000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1775000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
232000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
19610000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
0 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
4021000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
0 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
5853000 | usd |
| CY2024Q1 | blue |
Factoring Agreement Cash Receipts Collected
FactoringAgreementCashReceiptsCollected
|
1120000 | usd |
| CY2023Q1 | blue |
Factoring Agreement Cash Receipts Collected
FactoringAgreementCashReceiptsCollected
|
0 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
868000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
|
0 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
|
92972000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-655000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
82136000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
71316000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
0 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
2669000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
0 | usd |
| CY2024Q1 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
2250000 | usd |
| CY2023Q1 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
0 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
0 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
7000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Other Debt
ProceedsFromOtherDebt
|
15120000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Other Debt
ProceedsFromOtherDebt
|
0 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
22210000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
15280000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
64645000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
115176000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-10686000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
125954000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
274597000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
158445000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
263911000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
284399000 | usd |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
212047000 | usd |
| CY2023Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
239045000 | usd |
| CY2024Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
3866000 | usd |
| CY2023Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1417000 | usd |
| CY2024Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
47998000 | usd |
| CY2023Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
43937000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
263911000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
284399000 | usd |
| CY2024Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
0 | usd |
| CY2023Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
189000 | usd |
| CY2024Q1 | blue |
Offering Expenses Included In Accounts Payable And Accrued Expenses
OfferingExpensesIncludedInAccountsPayableAndAccruedExpenses
|
0 | usd |
| CY2023Q1 | blue |
Offering Expenses Included In Accounts Payable And Accrued Expenses
OfferingExpensesIncludedInAccountsPayableAndAccruedExpenses
|
523000 | usd |
| CY2024Q1 | blue |
Disposition Of Assets Expenses Incurred During Noncash Or Partial Noncash Transaction
DispositionOfAssetsExpensesIncurredDuringNoncashOrPartialNoncashTransaction
|
0 | usd |
| CY2023Q1 | blue |
Disposition Of Assets Expenses Incurred During Noncash Or Partial Noncash Transaction
DispositionOfAssetsExpensesIncurredDuringNoncashOrPartialNoncashTransaction
|
43000 | usd |
| CY2024Q1 | blue |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability Including Adjustments For Remeasurement
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityIncludingAdjustmentsForRemeasurement
|
38669000 | usd |
| CY2023Q1 | blue |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability Including Adjustments For Remeasurement
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityIncludingAdjustmentsForRemeasurement
|
-214000 | usd |
| CY2024Q1 | blue |
Beneficiary Interest Obtained In Transferred Invoices
BeneficiaryInterestObtainedInTransferredInvoices
|
1680000 | usd |
| CY2023Q1 | blue |
Beneficiary Interest Obtained In Transferred Invoices
BeneficiaryInterestObtainedInTransferredInvoices
|
0 | usd |
| CY2024Q1 | blue |
Beneficial Interest Amount Derecognized
BeneficialInterestAmountDerecognized
|
15120000 | usd |
| CY2023Q1 | blue |
Beneficial Interest Amount Derecognized
BeneficialInterestAmountDerecognized
|
0 | usd |
| CY2024Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
1000 | usd |
| CY2023Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
2000 | usd |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
Description of the business<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bluebird bio, Inc. (the “Company” or “bluebird”) was incorporated in Delaware on April 16, 1992, and is headquartered in Somerville, Massachusetts. The Company is a biotechnology company committed to researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, and commercialization of its approved products, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates, provide selling, general and administrative support for these operations and market and commercially manufacture and distribute its approved products.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s programs in severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel) as a treatment for β-thalassemia; LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel) as a treatment for sickle cell disease ("SCD"); and SKYSONA (elivaldogene autotemcel, also known as eli-cel) as a treatment for cerebral adrenoleukodystrophy ("CALD"). On August 17, 2022, ZYNTEGLO was approved by the U.S. Food and Drug Administration ("FDA") for the treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell transfusions. On September 16, 2022, the FDA granted Accelerated Approval of SKYSONA to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active CALD. On December 8, 2023, LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease and with a history of vaso-occlusive-events. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into an Open Market Sales Agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies") to sell shares of the Company’s common stock up to $125.0 million, from time to time, through an “at the market” equity offering program under which Jefferies will act as sales agent. As of March 31, 2024, the Company has made no sales pursuant to the Sales Agreement.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC ("Goldman") and J.P. Morgan Securities LLC, to sell 83.3 million shares of the Company's common stock. The Company received net proceeds of approximately $118.1 million. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company entered into a five-year term loan facility agreement with Hercules Capital, Inc. to secure debt financing for up to $175 million, available in four tranches. This is described in Note 8,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Term Loan Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Notes to Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred significant operating losses and negative operating cash flows. As of March 31, 2024, the Company had an accumulated deficit of $4.3 billion. During the three months ended March 31, 2024, the Company incurred a net loss of $69.8 million and used $74.7 million of cash in operations. As of March 31, 2024, the Company had cash and cash equivalents of $212.0 million. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's history of recurring operating losses and negative operating cash flows, its expectation to generate operating losses and negative operating cash flows, and the need for additional funding to support its planned operations raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that these consolidated financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include controlling spending, executing on commercial launch plans, and exploring additional financing options. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has based the estimated cash needs on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. As a result, the Company could deplete its capital resources sooner than it currently expects. Along with the Company's revenue from product sales, the Company expects to finance its future cash needs through the issuance of equity, or debt, or other alternative means. If the Company is unable to obtain funding on a timely basis, or if revenues from product sales are less than it has projected, the Company may be required to further revise its business plan and strategy, which may result in the Company significantly curtailing, delaying or discontinuing one or more of its research or development programs or the commercialization of any products or may result in the Company being unable to expand its operations or otherwise capitalize on its business opportunities. As a result, the Company's business, financial condition and results of operations could be materially affected. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</span></div> | |
| CY2024Q1 | blue |
Number Of Tranches
NumberOfTranches
|
4 | tranche |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-4300000000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-69800000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-74700000 | usd |
| CY2024Q1 | us-gaap |
Investments And Cash
InvestmentsAndCash
|
212000000.0 | usd |
| CY2024Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
| CY2024Q1 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification of Prior Year Presentation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation. Specifically, interest expense has been reclassified from interest income to interest expense in the consolidated statement of operations and comprehensive (loss) income. These reclassifications had no effect on the reported results of operations.</span></div> | |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and judgments are used in the following areas, among others: the alternative future use of assets used in research and development activities, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, gross-to-net revenue calculations, stock-based compensation expense, accrued expenses, income taxes, the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements, and the assessment of the likelihood and magnitude of losses that may be sustained upon resolution of contingencies.</span></div> | |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
18600000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
2300000 | usd |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
18561000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
2296000 | usd |
| CY2023Q4 | blue |
Contract With Customer Rebate Liability Current
ContractWithCustomerRebateLiabilityCurrent
|
5365000 | usd |
| CY2024Q1 | blue |
Provision For Contract With Customer Rebate Liability
ProvisionForContractWithCustomerRebateLiability
|
3780000 | usd |
| CY2024Q1 | blue |
Contract With Customer Payments Rebate Liability
ContractWithCustomerPaymentsRebateLiability
|
0 | usd |
| CY2024Q1 | blue |
Contract With Customer Rebate Liability Current
ContractWithCustomerRebateLiabilityCurrent
|
9145000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | usd |
| CY2023Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
-100000 | usd |
| CY2024Q1 | us-gaap |
Interest Receivable
InterestReceivable
|
300000 | usd |
| CY2023Q4 | us-gaap |
Interest Receivable
InterestReceivable
|
300000 | usd |
| CY2023Q1 | blue |
Interest Receivable Write Off
InterestReceivableWriteOff
|
0 | usd |
| CY2024Q1 | blue |
Interest Receivable Write Off
InterestReceivableWriteOff
|
0 | usd |
| CY2024Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
3177000 | usd |
| CY2023Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
2329000 | usd |
| CY2024Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
22146000 | usd |
| CY2023Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
17375000 | usd |
| CY2024Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
4982000 | usd |
| CY2023Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
3215000 | usd |
| CY2024Q1 | us-gaap |
Inventory Net
InventoryNet
|
30305000 | usd |
| CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
22919000 | usd |
| CY2024Q1 | blue |
Factoring Agreement Cash Receipts Collected Prior To Consideration
FactoringAgreementCashReceiptsCollectedPriorToConsideration
|
15100000 | usd |
| CY2024Q1 | blue |
Factoring Agreement Payable Current Derecognized
FactoringAgreementPayableCurrentDerecognized
|
15100000 | usd |
| CY2024Q1 | blue |
Beneficiary Interest Obtained
BeneficiaryInterestObtained
|
1600000 | usd |
| CY2024Q1 | blue |
Factoring Agreement Cash Receipts Collected
FactoringAgreementCashReceiptsCollected
|
1100000 | usd |
| CY2024Q1 | blue |
Factoring Agreement Receivable Uncollectable Amounts Net Of Accrued Fees
FactoringAgreementReceivableUncollectableAmountsNetOfAccruedFees
|
100000 | usd |
| CY2024Q1 | blue |
Factoring Agreement Receivable Current Net Of Uncollectible
FactoringAgreementReceivableCurrentNetOfUncollectible
|
1100000 | usd |
| CY2024Q1 | blue |
Factoring Agreement Gain Loss On Sale Of Invoices
FactoringAgreementGainLossOnSaleOfInvoices
|
-300000 | usd |
| CY2024Q1 | blue |
Factoring Agreement Servicing Fees
FactoringAgreementServicingFees
|
400000 | usd |
| CY2024Q1 | blue |
Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
|
22481000 | usd |
| CY2023Q4 | blue |
Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
|
24824000 | usd |
| CY2024Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
10876000 | usd |
| CY2023Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
19972000 | usd |
| CY2024Q1 | blue |
Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
|
5453000 | usd |
| CY2023Q4 | blue |
Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
|
8391000 | usd |
| CY2024Q1 | blue |
Accrued Rebates Current
AccruedRebatesCurrent
|
9194000 | usd |
| CY2023Q4 | blue |
Accrued Rebates Current
AccruedRebatesCurrent
|
5365000 | usd |
| CY2024Q1 | us-gaap |
Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
|
7090000 | usd |
| CY2023Q4 | us-gaap |
Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
|
2531000 | usd |
| CY2024Q1 | us-gaap |
Customer Refund Liability Current
CustomerRefundLiabilityCurrent
|
0 | usd |
| CY2023Q4 | us-gaap |
Customer Refund Liability Current
CustomerRefundLiabilityCurrent
|
5600000 | usd |
| CY2024Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
9002000 | usd |
| CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
6505000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
64096000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
73188000 | usd |
| CY2024Q1 | blue |
Number Of Additional Controlled Environment Rooms
NumberOfAdditionalControlledEnvironmentRooms
|
2 | room |
| CY2024Q1 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
4347000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
4267000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
14328000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
5216000 | usd |
| CY2024Q1 | blue |
Finance Lease Cost
FinanceLeaseCost
|
18675000 | usd |
| CY2023Q1 | blue |
Finance Lease Cost
FinanceLeaseCost
|
9483000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
9486000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
11470000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
9486000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
11470000 | usd |
| CY2024Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
6043000 | usd |
| CY2023Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
6862000 | usd |
| CY2024Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
76000 | usd |
| CY2023Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
52000 | usd |
| CY2024Q1 | us-gaap |
Lease Cost
LeaseCost
|
34280000 | usd |
| CY2023Q1 | us-gaap |
Lease Cost
LeaseCost
|
27867000 | usd |
| CY2024Q1 | us-gaap |
Sublease Income
SubleaseIncome
|
10346000 | usd |
| CY2023Q1 | us-gaap |
Sublease Income
SubleaseIncome
|
10108000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
2844000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
6361000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
1411000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
3352000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
22210000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
15280000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y5M1D | |
| CY2023Q1 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y3M18D | |
| CY2024Q1 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.1445 | |
| CY2023Q1 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.1513 | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P6Y9M | |
| CY2023Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P7Y7M2D | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0700 | |
| CY2023Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0704 | |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
28492000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
|
102277000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
37084000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
41270000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
35719000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
3422000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
36742000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
2548000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
37795000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
1043000 | usd |
| CY2024Q1 | blue |
Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
|
81986000 | usd |
| CY2024Q1 | blue |
Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
|
0 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
257818000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
150560000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
52772000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
10259000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
205046000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
140301000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P3Y | |
| CY2024Q1 | us-gaap |
Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
|
56800000 | usd |
| CY2024Q1 | us-gaap |
Unrecorded Unconditional Purchase Obligation Due In Remainder Of Fiscal Year
UnrecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear
|
0 | usd |
| CY2024Q1 | us-gaap |
Unrecorded Unconditional Purchase Obligation Balance On First Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary
|
13763000 | usd |
| CY2024Q1 | us-gaap |
Unrecorded Unconditional Purchase Obligation Balance On Second Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary
|
17858000 | usd |
| CY2024Q1 | us-gaap |
Unrecorded Unconditional Purchase Obligation Balance On Third Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary
|
17858000 | usd |
| CY2024Q1 | us-gaap |
Unrecorded Unconditional Purchase Obligation Balance On Fourth Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary
|
7310000 | usd |
| CY2024Q1 | blue |
Unrecorded Unconditional Purchase Obligation To Be Paid After Year Four
UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour
|
0 | usd |
| CY2024Q1 | us-gaap |
Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
|
56789000 | usd |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3800000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5400000 | usd |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3761000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5391000 | usd |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3761000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5391000 | usd |
| CY2024Q1 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
300000 | usd |
| CY2023Q1 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
500000 | usd |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4227000 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
14.16 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2572000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.56 | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
229000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
16.55 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6570000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.16 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1871000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
22.75 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
6570000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
9.16 | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
16022000 | shares |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.36 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.36 | |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
18900000 | usd |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
102900000 | shares |
| CY2023Q1 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
400000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
103300000 | shares |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.18 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.18 | |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
2296000 | usd |
| CY2023Q1 | us-gaap |
Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
|
85000 | usd |
| CY2023Q1 | us-gaap |
Revenues
Revenues
|
2381000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
5512000 | usd |
| CY2023Q1 | us-gaap |
Gross Profit
GrossProfit
|
-3131000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
41587000 | usd |
| CY2023Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
37467000 | usd |
| CY2023Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
79054000 | usd |
| CY2023Q1 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
92930000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
10745000 | usd |
| CY2023Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2828000 | usd |
| CY2023Q1 | us-gaap |
Interest Expense
InterestExpense
|
4270000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
9627000 | usd |
| CY2023Q1 | us-gaap |
Income Loss Attributable To Parent
IncomeLossAttributableToParent
|
18930000 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
18930000 | usd |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.18 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.18 | |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
102920000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
103303000 | shares |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
|
0 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
984000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
984000 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
19914000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
134333000 | usd |
| CY2023Q1 | blue |
Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
|
-195000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
7000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
227000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
130291000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5843000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
984000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
18930000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
290420000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
18930000 | usd |
| CY2023Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
6172000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5391000 | usd |
| CY2023Q1 | blue |
Noncash Research And Development Expense Finance Lease
NoncashResearchAndDevelopmentExpenseFinanceLease
|
1441000 | usd |
| CY2023Q1 | blue |
Noncash Lease Expense
NoncashLeaseExpense
|
7423000 | usd |
| CY2023Q1 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
92930000 | usd |
| CY2023Q1 | blue |
Inventory Excess Valuation Reserves
InventoryExcessValuationReserves
|
2583000 | usd |
| CY2023Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-237000 | usd |
| CY2023Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
108000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
3689000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
5331000 | usd |
| CY2023Q1 | blue |
Lessee Increase Decrease In Operating Lease Right Of Use Asset
LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset
|
0 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1260000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-7206000 | usd |
| CY2023Q1 | blue |
Increase Decrease Accrued Interest Payable Under Finance Lease
IncreaseDecreaseAccruedInterestPayableUnderFinanceLease
|
-915000 | usd |
| CY2023Q1 | blue |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-6361000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-85000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-71358000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
232000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
19610000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
4021000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
5853000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
868000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
|
92972000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
82136000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
7000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
15280000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
115176000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
125954000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
158445000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
284399000 | usd |
| CY2023Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
239045000 | usd |
| CY2023Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1417000 | usd |
| CY2023Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
43937000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
284399000 | usd |
| CY2023Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
189000 | usd |
| CY2023Q1 | us-gaap |
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
523000 | usd |
| CY2023Q1 | blue |
Disposition Of Assets Expenses Incurred During Noncash Or Partial Noncash Transaction
DispositionOfAssetsExpensesIncurredDuringNoncashOrPartialNoncashTransaction
|
43000 | usd |
| CY2023Q1 | blue |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability Including Adjustments For Remeasurement
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityIncludingAdjustmentsForRemeasurement
|
-214000 | usd |
| CY2023Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
2000 | usd |
| CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false |
